Akeso marks profit milestone with swift rights issue
Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs Key Takeaways: Akeso swung to an…
Fast-growing Duoning Biotech seeks winning formula for pricey IPO
The provider of bioprocessing services for the drugs sector has been expanding rapidly via aggressive M&A, backed by big-name investors Key Takeaways: WuXi Biologics is Duoning Biotechnology’s biggest client and…
After One-Off Cash Infusions, YZY Biopharma Looks for More Funds From IPO
The cash-challenged biotech firm specializing in BsAbs and immuno-oncology therapies is turning to a Hong Kong listing to try to replenish its coffersKey Takeaways:YZY Biopharma has filed for a Hong…
RELATED ARTICLES
-
HBM gets health boost from drug licensing deals
2142.HK -
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
-
Sales success comes with side effects for drug maker BeiGene
BGNE.US 6160.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
